We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Biogen Inc (BIIB) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$260 after a previous close of US$269.85. During the day the price has varied from a low of USD257.03 to a high of USD264.51. The latest price was USD260.635 (25 minute delay). Biogen is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Biogen
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Biogen. Find the share by name or ticker symbol: BIIB. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Biogen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Biogen, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Biogen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Biogen key stats
- Compare share trading platforms
- Is Biogen stock a buy or sell?
- Biogen performance over time
- Can I short Biogen shares?
- Is Biogen suitable for ethical investing?
- Are Biogen shares over-valued?
- Biogen's financials
- How volatile are Biogen shares?
- Does Biogen pay a dividend?
- Have Biogen shares ever split?
- Other common questions
Biogen share priceUse our graph to track the performance of BIIB stocks over time.
Biogen shares at a glance
|52-week range||US$223.25 - US$335|
|50-day moving average||US$268.9337|
|200-day moving average||US$264.5757|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$24.8|
Compare share trading platforms to buy stock
Is it a good time to buy Biogen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Biogen price performance over time
|1 week (2021-04-15)||-3.63%|
|1 month (2021-03-19)||-2.41%|
|3 months (2021-01-22)||-3.27%|
|6 months (2020-10-22)||-2.31%|
|1 year (2020-04-22)||-12.54%|
|2 years (2019-04-22)||13.91%|
|3 years (2018-04-20)||-0.91%|
|5 years (2016-04-22)||0.09%|
Is Biogen under- or over-valued?
Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biogen's P/E ratio
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Biogen shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biogen's PEG ratio
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$5.1 billion (£3.7 billion).
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$13.4 billion|
|Operating margin TTM||34.63%|
|Gross profit TTM||US$11.6 billion|
|Return on assets TTM||11.22%|
|Return on equity TTM||33.8%|
|Market capitalisation||US$40.3 billion|
TTM: trailing 12 months
Shorting Biogen shares
There are currently 3.6 million Biogen shares held short by investors – that's known as Biogen's "short interest". This figure is 8% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting Biogen shares can be evaluated.
Biogen's "short interest ratio" (SIR)
Biogen's "short interest ratio" (SIR) is the quantity of Biogen shares currently shorted divided by the average quantity of Biogen shares traded daily (recently around 1.3 million). Biogen's SIR currently stands at 2.84. In other words for every 100,000 Biogen shares traded daily on the market, roughly 2840 shares are currently held short.
However Biogen's short interest can also be evaluated against the total number of Biogen shares, or, against the total number of tradable Biogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biogen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biogen shares in existence, roughly 20 shares are currently held short) or 0.0241% of the tradable shares (for every 100,000 tradable Biogen shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biogen.
Find out more about how you can short Biogen stock.
Biogen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Biogen's total ESG risk score
Total ESG risk: 22.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 22.95 (as at 12/31/2018) is pretty good – landing it in it in the 34th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Biogen's environmental score
Environmental score: 1.02/100
Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Biogen's social score
Social score: 13.48/100
Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Biogen's governance score
Governance score: 7.45/100
Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Biogen's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||22.95|
|Total ESG percentile||33.82|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
Biogen share dividends
We're not expecting Biogen to pay a dividend over the next 12 months.
Have Biogen's shares ever split?
Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.
Biogen share price volatility
Over the last 12 months, Biogen's shares have ranged in value from as little as US$223.25 up to US$335. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.4368. This would suggest that Biogen's shares are less volatile than average (for this exchange).
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
Ask an Expert